The renewal confirms the facility’s continued ability to deliver GLP-compliant bioanalytical testing to support global preclinical research programs.
KCAS Bio has reaffirmed its commitment to regulatory excellence and scientific quality with the successful renewal of its Good Laboratory Practice (GLP) compliance statement for its European facility in Lyon, France. The renewal confirms that the site continues to operate in full compliance with Directive 2004/9/EC, the European framework governing the inspection and verification of GLP standards for laboratories conducting safety testing. This milestone strengthens the organization’s ability to support global pharmaceutical and biotechnology companies in generating high-quality bioanalytical data essential for drug development and regulatory submissions.
Strengthening GLP Compliance for Drug Development
The renewed GLP compliance statement verifies that the Lyon facility maintains the necessary standards to perform GLP-compliant bioanalytical testing for preclinical studies. These studies play a critical role in evaluating the safety, pharmacokinetics, and toxicokinetics of drug candidates before they advance into human clinical trials.
GLP guidelines are internationally recognized quality standards designed to ensure that laboratory studies are conducted with consistency, integrity, and traceability. Compliance with these guidelines ensures that data generated from laboratory research can be trusted by regulatory authorities when assessing the safety of new medicines.
By successfully renewing its compliance declaration, KCAS Bio confirms that its laboratory systems, documentation practices, personnel training, and operational processes meet the rigorous requirements established by European regulatory bodies. The renewal reinforces the facility’s capability to deliver reliable data that supports the advancement of investigational therapies through the development pipeline.
Maintaining “A” Level Compliance
During the inspection process, the Lyon testing facility once again achieved an “A” level compliance rating, which represents the highest level of adherence to GLP standards. This rating demonstrates that the laboratory maintains exemplary operational practices and continues to meet the strict expectations required for regulatory-grade bioanalytical research.
Achieving and maintaining this level of compliance is particularly important for pharmaceutical and biotechnology sponsors who rely on laboratory partners to generate accurate and reproducible data. Such data is essential when preparing submissions for regulatory approval, including Investigational New Drug (IND) applications, which must include robust preclinical safety and bioanalytical information before clinical trials can begin.
The renewal ensures that sponsors working with KCAS Bio can continue to rely on the Lyon facility for the generation of high-quality data suitable for submission to regulatory authorities worldwide. Reliable GLP-compliant data reduces uncertainty in the regulatory review process and supports informed decision-making throughout drug development.
Long-Standing Commitment to Quality Standards
The GLP compliance renewal is complemented by the site’s long-standing ISO 9001:2015 certification, which the Lyon facility has maintained without interruption for more than 15 years. ISO 9001 is one of the world’s most widely recognized quality management system standards, ensuring that organizations maintain consistent operational procedures, risk management practices, and customer-focused performance.
Together, GLP compliance and ISO certification highlight the laboratory’s dedication to quality management across all stages of research and development. Maintaining both standards simultaneously requires ongoing internal audits, staff training, equipment calibration, and strict documentation practices.
The combination of these certifications demonstrates KCAS Bio’s long-term commitment to maintaining a rigorous scientific environment where accuracy, traceability, and regulatory readiness are integral to every study conducted.
Leadership Perspective on the Renewal
According to Dr. Mouhssin Oufir, General Manager of KCAS Bio’s Lyon facility and GLP Test Facility Manager, the renewal reflects the organization’s continuous focus on delivering scientifically robust and regulatory-compliant data.
Dr. Oufir emphasized that maintaining GLP compliance is essential for sponsors developing innovative therapeutics. He noted that bioanalytical data generated during preclinical studies must meet the highest standards of quality and credibility, as such information forms the foundation for regulatory submissions and subsequent clinical development.
He explained that achieving and sustaining the “A” compliance rating demonstrates that the facility’s infrastructure, operational procedures, and scientific teams are aligned to deliver data that sponsors can trust. This level of confidence allows pharmaceutical companies to advance their development programs with assurance that their analytical results will meet regulatory expectations.
Supporting Diverse Preclinical Research Programs
The Lyon facility plays an important role in supporting toxicokinetic and bioanalytical studies across a wide range of animal models commonly used in preclinical research. These include species such as mice, rats, rabbits, dogs, miniature pigs, and non-human primates including marmosets and crab-eating macaques.
Toxicokinetic (TK) studies help researchers understand how drug candidates behave within a biological system, including how they are absorbed, distributed, metabolized, and eliminated. These insights are crucial for evaluating potential safety risks and determining appropriate dosing strategies before human clinical trials.
By providing GLP-compliant TK and bioanalytical services, the Lyon facility contributes essential data that informs early-stage decision-making for pharmaceutical and biotechnology sponsors.
Expertise Across Multiple Therapeutic Modalities
Beyond traditional small-molecule drug analysis, KCAS Bio’s Lyon laboratory offers advanced bioanalytical capabilities across a broad range of modern therapeutic modalities. These include large-molecule biologics, cell and gene therapies, vaccines, and oligonucleotide-based treatments.
The growing diversity of drug technologies has increased the complexity of bioanalytical testing. Each therapeutic modality requires specialized analytical techniques and validated methodologies to accurately measure drug concentrations and biological responses.
KCAS Bio’s expertise in these advanced areas allows sponsors to rely on the Lyon facility for sophisticated analytical services tailored to modern drug development. The ability to analyze both traditional and emerging therapeutic platforms positions the laboratory as a versatile partner for innovative pharmaceutical research.
Enabling Confident Regulatory Submissions
High-quality bioanalytical data generated during preclinical studies serves as the backbone of regulatory submissions. Authorities reviewing IND applications or other development filings require clear evidence that laboratory studies were conducted according to recognized standards such as GLP.
The renewal of the GLP compliance statement ensures that the Lyon site remains fully qualified to generate such data. Sponsors working with KCAS Bio can therefore submit their study results to regulatory agencies with confidence that the data meets internationally recognized quality requirements.
Reliable data not only supports regulatory approval processes but also helps pharmaceutical companies make informed strategic decisions regarding candidate selection, dosing strategies, and development timelines.
Continuing Support for Global Drug Development
With the renewed GLP compliance declaration and long-standing ISO certification, KCAS Bio continues to strengthen its reputation as a trusted partner in the global drug development ecosystem. The Lyon facility remains a key hub for bioanalytical testing and toxicokinetic studies supporting innovative therapeutic programs.
By maintaining rigorous quality standards and expanding expertise across diverse therapeutic modalities, KCAS Bio enables sponsors to advance promising drug candidates from early preclinical research through clinical development. The company’s commitment to scientific rigor and regulatory compliance ensures that the data generated at its laboratories remains reliable, reproducible, and suitable for regulatory review.
As the pharmaceutical industry continues to evolve with new technologies and therapeutic approaches, facilities like the KCAS Bio Lyon site play a critical role in bridging scientific discovery and clinical application. Through ongoing adherence to GLP standards and continuous investment in analytical capabilities, KCAS Bio is well positioned to support the next generation of life-saving medicines.